Cargando…

Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?

This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if ta...

Descripción completa

Detalles Bibliográficos
Autor principal: Roth, Bryan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Les Laboratoires Servier 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181824/
https://www.ncbi.nlm.nih.gov/pubmed/17117612
_version_ 1782212820611366912
author Roth, Bryan L.
author_facet Roth, Bryan L.
author_sort Roth, Bryan L.
collection PubMed
description This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia.
format Online
Article
Text
id pubmed-3181824
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Les Laboratoires Servier
record_format MEDLINE/PubMed
spelling pubmed-31818242011-10-27 Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Roth, Bryan L. Dialogues Clin Neurosci Pharmacological Aspects This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia. Les Laboratoires Servier 2006-09 /pmc/articles/PMC3181824/ /pubmed/17117612 Text en Copyright: © 2006 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pharmacological Aspects
Roth, Bryan L.
Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
title Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
title_full Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
title_fullStr Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
title_full_unstemmed Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
title_short Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
title_sort contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
topic Pharmacological Aspects
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181824/
https://www.ncbi.nlm.nih.gov/pubmed/17117612
work_keys_str_mv AT rothbryanl contributionsofmolecularbiologytoantipsychoticdrugdiscoverypromisesfulfilledorunfulfilled